Welcome to our dedicated page for Scilex Holding Co SEC filings (Ticker: SCLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Scilex Holding Company (SCLX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including Forms 8-K, registration statements, proxy materials and other key documents filed with the U.S. Securities and Exchange Commission. Scilex is an emerging growth company focused on non-opioid pain management products and related pipeline candidates, and its filings give detailed insight into corporate actions, financing structures and strategic agreements.
For investors tracking Scilex’s capital structure, recent Form 8-K reports describe warrant inducement agreements, exercises of existing warrants, issuance of new unregistered warrants, and the terms of non-recourse loan and securities pledge agreements with The St. James Bank & Trust Company Ltd. These filings outline interest rates tied to the 12-month Secured Overnight Financing Rate, maturity dates, pledged collateral (including Scilex and Datavault AI shares), events of default, and lender remedies.
Filings also document Scilex’s Datavault AI transactions, including a Securities Purchase Agreement for Datavault common stock and a pre-funded warrant, and a License Agreement granting Scilex a worldwide, exclusive license to Datavault patents and know-how for biotech, biopharma, genetic, diagnostic and data-related markets. The associated 8-Ks summarize consideration, royalty structures, milestones and termination conditions.
Scilex’s registration statements, such as its S-1 filing, and proxy statements (DEF 14A) provide further detail on equity incentive plans, option repricing proposals, voting rights for common and preferred stock, and governance matters. These documents complement the company’s periodic reports by explaining how management structures compensation and seeks shareholder approvals for key actions.
On Stock Titan, AI-powered tools can help interpret lengthy filings by highlighting material agreements, financial obligations, equity issuances, and risk disclosures. Users can quickly locate information on warrant terms, loan covenants, Datavault-related agreements, and other items that shape Scilex’s financial profile and strategic direction, without manually parsing every page of each filing.
Scilex Holding Company entered a material License Agreement with Datavault AI Inc. on November 3, 2025. Datavault granted Scilex a worldwide, exclusive, non-transferable license, with sublicense rights, to use specified patents and know‑how to research, develop, and commercialize Proprietary Materials across a defined Target Market spanning biotechnology, biopharmaceutical, genetic, diagnostic, and data‑related industries.
Scilex will pay a non‑refundable license fee of
The agreement may terminate earlier upon insolvency, uncured material breach, failure to make required payments within 15 days, or if Scilex does not achieve and maintain annual royalty payments of at least
Scilex Holding Company filed a prospectus supplement to update prior S-1 prospectuses by attaching a new Form 8-K. The 8-K discloses termination of its July 22, 2025 equity line of credit with Tumim Stone Capital.
Under a Termination Agreement dated October 30, 2025, Scilex will pay $2.7 million in cash to Tumim in lieu of issuing 150,000 commitment shares. Payments are scheduled as $500,000 on or before October 31, 2025, $500,000 on or before November 14, 2025, and $1.7 million on or before December 15, 2025. The original agreements terminate once the cash is paid in full.
If Scilex does not pay the full amount by December 15, 2025, it must issue the 150,000 commitment shares within two business days and amend the related registration statement. The company states the termination reflects that it no longer needs to raise additional capital under the equity line at this time.
Scilex Holding Company terminated its July 22, 2025 equity line of credit with Tumim Stone Capital. Instead of issuing 150,000 commitment shares, Scilex agreed to pay $2.7 million in cash: $500,000 on or before October 31, 2025, $500,000 on or before November 14, 2025, and $1.7 million on or before December 15, 2025. The termination becomes effective after full payment.
If Scilex does not pay the full amount by December 15, 2025, it must issue the 150,000 commitment shares within two business days and file an amendment to the registration statement. The company stated it no longer needs to raise additional capital under the original agreements at this time.
This prospectus supplement updates prior prospectuses by attaching the related Form 8‑K.
Scilex Holding Company terminated its equity line of credit with Tumim Stone Capital and agreed to pay $2.7 million in cash instead of issuing 150,000 commitment shares.
The payment schedule is $500,000 on or before October 31, 2025, $500,000 on or before November 14, 2025, and $1,700,000 on or before December 15, 2025. If the total is not paid by December 15, 2025, Scilex must issue the 150,000 shares within two business days and file a related registration amendment. The company stated it no longer needs to raise additional capital under these agreements at this time.
This prospectus supplement updates three existing S‑1 prospectuses by attaching the Current Report on Form 8‑K that describes the termination.
Scilex Holding Company terminated its equity line of credit with Tumim Stone Capital. The parties signed a Termination Agreement on October 30, 2025 under which the agreements will end upon Scilex’s payment of $2.7 million to Tumim in lieu of issuing 150,000 commitment shares.
The cash payments are scheduled as $500,000 on or before October 31, 2025, $500,000 on or before November 14, 2025, and the remaining $1.7 million on or before December 15, 2025. The company stated the termination is because it no longer needs to raise additional capital under these agreements at this time.
Scilex Holding Company called a virtual special meeting for December 11, 2025 at 9:00 a.m. PT to seek stockholder approval to reprice certain stock options granted under the 2022 Equity Incentive Plan and to approve a potential adjournment to solicit additional proxies if needed.
The repricing would reset the exercise price of eligible options to the closing price on the approval date. As context, on October 17, 2025, the Common Stock closed at $12.78 per share, while certain options carry a $282.80 exercise price. The company reports 1,511,113 options outstanding across plans, of which approximately 289,405 under the 2022 Plan are eligible (about 19% of outstanding options). Directors and executive officers as a group hold about 271,839 of these eligible options.
Approval of the option repricing requires a majority of votes cast. The adjournment proposal requires a majority of voting power present. Abstentions have no effect on the option repricing outcome but count against the adjournment proposal. Brokers may not vote uninstructed shares on the option repricing but may do so on adjournment. Only holders as of November 3, 2025 may vote.
Scilex Holding Co (SCLX) director Wu Yue Alexander received a grant of 20,000 nonstatutory stock options on
Scilex Holding Co. reported a grant of an incentive stock option to Stephen Ma, who serves as CFO, COO and a director. The option, dated 10/08/2025, covers 60,000 shares of common stock with an exercise price of
The option cannot be exercised until the issuer's outstanding indebtedness under a Senior Secured Promissory Note to Oramed Pharmaceuticals and the Tranche B Senior Secured Convertible Notes to several holders has been repaid in full. The option shows an exercisable date of
Director Chun Jay received a grant of a nonstatutory stock option to purchase 20,000 shares of common stock with an exercise price of
Insider option grant and vesting conditions. The CEO and President, Ji Henry, received an incentive stock option to buy 120,000 shares of Scilex Holding Co common stock at